MedTrace Logo

A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer

NCT00383487 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-01-28

No results posted yet for this study

Summary

To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.

Conditions

Interventions

DRUG

Calcitriol

0.5 micrograms/kilogram q weekly

DRUG

Naproxen-n-butyl nitrate

400 mg BID, oral

Sponsors & Collaborators

Principal Investigators

  • Dr. Sandy Srinivas · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2007-07-31
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00383487 on ClinicalTrials.gov